Objectives: To investigate current practices and attitudes regarding use of adjuvant immunotherapy and prognostic gene expression profile (GEP) testing among melanoma medical and surgical oncologists.
Methods: An anonymous RedCap-based survey was emailed to ~300 melanoma experts.
Results: Respondents generally favored adjuvant immunotherapy over observation (73% for all Stage IIIA, 50% for Stage IIB/IIC) and cited a minimum 10-year recurrence risk of 11%-20% (48%) or 21%-30% (33%) to justify treatment, but acknowledged that risks of serious adverse events may outweigh potential benefits for some Stage IIB/IIC patients. While GEP test results did not strongly influence decision-making regarding follow-up or intervention, most were receptive to randomized trials using GEP testing to identify subsets of Stage IIB/IIC (74%) and Stage IB/IIA (54%) patients who may not or may, respectively, benefit from adjuvant therapy.
Conclusion: Although most respondents do not routinely use GEP testing, many would participate in clinical trials to determine clinical utility.
Keywords: adjuvant therapy; clinical trial; gene expression profiling; melanoma.
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.